Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address black034@mc.duke.edu

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994

Publications

Nolen, Brian M., Jeffrey R. Marks, Shlomo Ta’san, Alex Rand, The Minh Luong, Yun Wang, Kimberly Blackwell, and Anna E. Lokshin. “Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer..” Breast Cancer Research : Bcr 10, no. 3 (January 2008). https://doi.org/10.1186/bcr2096.

PMID
18474099
Full Text

Blackwell, Kimberly L. “The significance of distant metastases in breast cancer..” Breast (Edinburgh, Scotland) 17 Suppl 1 (January 2008): S1–2. https://doi.org/10.1016/s0960-9776(08)70001-8.

PMID
18279762
Full Text

Herold, Christina I., and Kimberly L. Blackwell. “The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer..” Breast (Edinburgh, Scotland) 17 Suppl 1 (January 2008): S15–24. https://doi.org/10.1016/s0960-9776(08)70004-3.

PMID
18279763
Full Text

Morse, Michael A., Amy Hobeika, Takuya Osada, Donna Niedzwiecki, Paul Kelly Marcom, Kimberly L. Blackwell, Carey Anders, Gayathri R. Devi, H Kim Lyerly, and Timothy M. Clay. “Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2..” J Transl Med 5 (September 6, 2007). https://doi.org/10.1186/1479-5876-5-42.

PMID
17822557
Full Text

Dressman, Holly K., Christopher Hans, Andrea Bild, John A. Olson, Eric Rosen, P Kelly Marcom, Vlayka B. Liotcheva, et al. “Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy..” Clin Cancer Res 12, no. 3 Pt 1 (February 1, 2006): 819–26. https://doi.org/10.1158/1078-0432.CCR-05-1447.

PMID
16467094
Full Text

Hardee, Matthew E., Zahid N. Rabbani, Murat O. Arcasoy, John P. Kirkpatrick, Zeljko Vujaskovic, Mark W. Dewhirst, and Kimberly L. Blackwell. “Erythropoietin inhibits apoptosis in breast cancer cells via an Akt-dependent pathway without modulating in vivo chemosensitivity..” Mol Cancer Ther 5, no. 2 (February 2006): 356–61. https://doi.org/10.1158/1535-7163.MCT-05-0196.

PMID
16505109
Full Text

Kirkpatrick, John P., Matthew E. Hardee, Stacey A. Snyder, Catherine M. Peltz, Yulin Zhao, David M. Brizel, Mark W. Dewhirst, and Kimberly L. Blackwell. “The effect of darbepoetin alfa on growth, oxygenation and radioresponsiveness of a breast adenocarcinoma..” Radiat Res 165, no. 2 (February 2006): 192–201.

PMID
16518899
Scholars@Duke

Hardee, Matthew E., Murat O. Arcasoy, Kimberly L. Blackwell, John P. Kirkpatrick, and Mark W. Dewhirst. “Erythropoietin biology in cancer..” Clin Cancer Res 12, no. 2 (January 15, 2006): 332–39. https://doi.org/10.1158/1078-0432.CCR-05-1771.

PMID
16428469
Full Text

Craciunescu, O., T. Raidy, D. Brizel, K. Blackwell, Z. Vujaskovic, T. Wong, E. Jones, N. Larrier, J. Macfall, and M. Dewhirst. “SU‐FF‐J‐125: Therapy Assessment Using a Full Time Point (fTP) Pharmacokinetic Analysis of Dynamic Contrast‐Enhanced Magnetic Resonance Imaging (DCE‐MRI): Role of Region of Interest (ROI) Selection in Three Tumor Sites.” In Medical Physics, Vol. 33, 2006. https://doi.org/10.1118/1.2240901.

Full Text

Pages